To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia

NCT06409650 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Alopecia

Interventions

DRUG: KX-826 dosed at 2.5mg
DRUG: KX-826 dosed at 2.5mg
DRUG: KX-826 dosed at 5 mg
DRUG: KX-826 dosed at 5 mg
DRUG: Matching placebo to KX-826
DRUG: Matching placebo to KX-826

Sponsor

Suzhou Koshine Biomedica, Inc.